ES2193842B1 - Virus recombinante de la fiebre aftosa que carece del sitio antigenico a y su utilizacion como vacuna marcada. - Google Patents

Virus recombinante de la fiebre aftosa que carece del sitio antigenico a y su utilizacion como vacuna marcada.

Info

Publication number
ES2193842B1
ES2193842B1 ES200101495A ES200101495A ES2193842B1 ES 2193842 B1 ES2193842 B1 ES 2193842B1 ES 200101495 A ES200101495 A ES 200101495A ES 200101495 A ES200101495 A ES 200101495A ES 2193842 B1 ES2193842 B1 ES 2193842B1
Authority
ES
Spain
Prior art keywords
mouth disease
lacks
foot
recombinant
site
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
ES200101495A
Other languages
English (en)
Other versions
ES2193842A1 (es
Inventor
Eric Baranowski
Esteban Domingo Solans
Carmen Martin-Ruiz-Jarabo
Francisco Sobrino Castello
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Consejo Superior de Investigaciones Cientificas CSIC
Original Assignee
Consejo Superior de Investigaciones Cientificas CSIC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Consejo Superior de Investigaciones Cientificas CSIC filed Critical Consejo Superior de Investigaciones Cientificas CSIC
Priority to ES200101495A priority Critical patent/ES2193842B1/es
Publication of ES2193842A1 publication Critical patent/ES2193842A1/es
Application granted granted Critical
Publication of ES2193842B1 publication Critical patent/ES2193842B1/es
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/085—Picornaviridae, e.g. coxsackie virus, echovirus, enterovirus
    • C07K14/09—Foot-and-mouth disease virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Analytical Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Virus recombinante de la fiebre aftosa que carece del sitio antigénico A y su utilización como vacuna marcada. La presente invención proporciona un virus recombiante de la fiebre aftosa caracterizado por alteraciones antigénicas drásticas en el bucle G-H de la proteína de cápsida VP1 que afectan los epitopos de un sitio antigénico importante del virus de la fiebre aftosa (VFA), denominado sitio A en el VFA de serotipo C. Este virus recombinante de la fiebre aftosa que carece del sitio antigénico A pueden ser utilizado en la producción de vacunas marcadas para la protección contra la fiebre aftosa que permiten una distinción entre animales infectados y no infectados en poblaciones vacunadas. Además, este virus recombinante se puede utilizar para la producción de vacunas atenuadas o de vacunas inactivadas sin riesgos de escape viral.
ES200101495A 2001-06-28 2001-06-28 Virus recombinante de la fiebre aftosa que carece del sitio antigenico a y su utilizacion como vacuna marcada. Expired - Fee Related ES2193842B1 (es)

Priority Applications (1)

Application Number Priority Date Filing Date Title
ES200101495A ES2193842B1 (es) 2001-06-28 2001-06-28 Virus recombinante de la fiebre aftosa que carece del sitio antigenico a y su utilizacion como vacuna marcada.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES200101495A ES2193842B1 (es) 2001-06-28 2001-06-28 Virus recombinante de la fiebre aftosa que carece del sitio antigenico a y su utilizacion como vacuna marcada.

Publications (2)

Publication Number Publication Date
ES2193842A1 ES2193842A1 (es) 2003-11-01
ES2193842B1 true ES2193842B1 (es) 2005-06-01

Family

ID=29762941

Family Applications (1)

Application Number Title Priority Date Filing Date
ES200101495A Expired - Fee Related ES2193842B1 (es) 2001-06-28 2001-06-28 Virus recombinante de la fiebre aftosa que carece del sitio antigenico a y su utilizacion como vacuna marcada.

Country Status (1)

Country Link
ES (1) ES2193842B1 (es)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6284251B1 (en) * 1996-02-26 2001-09-04 Kansas State University Research Foundation BHV-1 gene-deleted virus vaccine

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
NILSSON, J. et al. Affinity fusion strategies for detection, purification and immobilization of recombinant proteins. Protein Expression and Purification, 1997, Vol. 11, páginas 1-16. *
RUIZ-JARABO, C.M. et al. Antigenic properties and population stability of a foot-and-mouth disease virus with an altered Arg-Gly-Asp receptor-recognition motif. Journal of General Virology, 1999, Vol. 80, páginas 1899-1909. *
ZHANG, Y. y KAPLAN, G. Characterization of replication-competent Hepatitis A virus constructs containing insertions at the N terminus of the polyprotein. Journal of Virology, 1998, Vol. 72, Nº 1, páginas 349-357. \\ A 8,9 *

Also Published As

Publication number Publication date
ES2193842A1 (es) 2003-11-01

Similar Documents

Publication Publication Date Title
Negro Is antibody-dependent enhancement playing a role in COVID-19 pathogenesis?
Pandey et al. Vaccination strategies to combat novel corona virus SARS-CoV-2
RU2565537C2 (ru) Конструкция
Metz et al. Effective chikungunya virus-like particle vaccine produced in insect cells
Lokhandwala et al. Induction of robust immune responses in swine by using a cocktail of adenovirus-vectored African swine fever virus antigens
Uddowla et al. A safe foot-and-mouth disease vaccine platform with two negative markers for differentiating infected from vaccinated animals
EA201990085A1 (ru) Рационально разработанный аттенуированный штамм вируса африканской лихорадки свиней для защиты от заражения исходным вирусным изолятом georgia 2007
Näslund et al. Vaccination with virus-like particles protects mice from lethal infection of Rift Valley Fever Virus
Robinson et al. Global Foot‐and‐Mouth Disease Research Update and Gap Analysis: 3‐Vaccines
JP2005525085A5 (es)
CY1116491T1 (el) Εμβολιο εναντι του αφθωδους πυρετου
Osterhaus et al. Vaccine strategies to overcome maternal antibody mediated inhibition of measles vaccine
Weger-Lucarelli et al. Identifying the role of E2 domains on alphavirus neutralization and protective immune responses
Schwartz et al. Potent vesicular stomatitis virus-based avian influenza vaccines provide long-term sterilizing immunity against heterologous challenge
MX2023007395A (es) Vacunas del virus de la peste porcina africana (ppa).
Cao et al. Evaluation of cross-protection against three topotypes of serotype O foot-and-mouth disease virus in pigs vaccinated with multi-epitope protein vaccine incorporated with poly (I: C)
Lee et al. Protective humoral immune response induced by an inactivated porcine reproductive and respiratory syndrome virus expressing the hypo-glycosylated glycoprotein 5
Collen et al. Heterotypic recognition of recombinant FMDV proteins by bovine T-cells: the polymerase (P3Dpol) as an immunodominant T-cell immunogen
Shahrudin et al. Gamma-irradiated rotavirus: A possible whole virus inactivated vaccine
PH12018502436A1 (en) Multivalent vaccines major swine viral diseases
Smith et al. A live attenuated influenza vaccine elicits enhanced heterologous protection when the internal genes of the vaccine are matched to those of the challenge virus
Cao et al. Improved neutralising antibody response against foot-and-mouth-disease virus in mice inoculated with a multi-epitope peptide vaccine using polyinosinic and poly-cytidylic acid as an adjuvant
Moreno et al. Recombinant Rift Valley fever viruses encoding bluetongue virus (BTV) antigens: Immunity and efficacy studies upon a BTV-4 challenge
NO20074855L (no) Anvendelse av et modifisert poxvirus for den rapide induksjonen av immunitet mot et poxvirus eller andre smittsomme midler
Kochinger et al. Vesicular stomatitis virus replicon expressing the VP2 outer capsid protein of bluetongue virus serotype 8 induces complete protection of sheep against challenge infection

Legal Events

Date Code Title Description
EC2A Search report published

Date of ref document: 20031101

Kind code of ref document: A1

FG2A Definitive protection

Ref document number: 2193842B1

Country of ref document: ES

FD2A Announcement of lapse in spain

Effective date: 20180807